Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA advisory panel to review Remoxy and Embeda

Executive Summary

FDA's Anesthetic and Life Support Drugs and Drug Safety and Risk Management advisory committees will review two abuse-resistant formulations of opioids for chronic pain Nov. 13 and 14: Pain Therapeutics/King Pharmaceuticals' Remoxy XRT (oxycodone hydrochloride controlled-release) and Alpharma Pharmaceuticals' Embeda (morphine sulfate extended-release with sequestered naltrexone hydrochloride). Risk management plans could play a large role in the votes, as indicated by the fate of Cephalon's analgesic Fentora (buccal fentanyl), earlier this year (1"The Pink Sheet" DAILY, Sept. 15, 2008)

Related Content




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts